• On March 13, 2026, Liquidia’s Chief Medical Officer Rajeev Saggar sold 35,365 shares of common stock for about US$1.28 million, trimming roughly one sixth of his direct holdings.
• This sizeable insider sale comes while Liquidia’s core business appears to be progressing, highlighted by YUTREPIA’s reach to more than 2,900 patients and two straight profitable quarters.
• We’ll now examine how this sizeable insider sale amid ongoing YUTREPIA momentum may influence Liquidia’s broader investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Liquidia Investment Narrative Recap

To own Liquidia, you have to believe YUTREPIA can sustain its current commercial traction while the company manages manufacturing scale up and legal or reimbursement uncertainties. Against that backdrop, Rajeev Saggar’s roughly one sixth reduction in his holdings does not appear to alter the near term focus on YUTREPIA execution or meaningfully change the key risk around how much of today’s prescription volume converts into durable, well reimbursed revenue.

The most relevant recent milestone alongside this insider sale is Liquidia’s fourth quarter 2025 earnings, where YUTREPIA helped lift quarterly revenue to US$92.02 million and deliver a second straight profitable quarter. That print reinforced the idea that early patient uptake and improving payer access are starting to show up in the income statement, which is central to how investors weigh YUTREPIA as a growth catalyst against concerns about long term demand and manufacturing capacity commitments.

Yet against this early momentum, investors still need to be aware of how payer decisions could quietly reshape YUTREPIA’s economics over time…

Liquidia's narrative projects $717.7 million revenue and $299.9 million earnings by 2029. This requires 118.1% yearly revenue growth and a $424.0 million earnings increase from $-124.1 million today.

Uncover how Liquidia's forecasts yield a $44.00 fair value, a 26% upside to its current price.

Exploring Other Perspectives

While consensus focuses on steady YUTREPIA uptake, the most optimistic analysts once penciled in revenue reaching about US$1.0 billion and earnings near US$603.6 million, underscoring how differently you might weigh this insider sale and the risk that reimbursement or market concentration plays out very differently than expected.

Explore 5 other fair value estimates on Liquidia - why the stock might be worth over 7x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Liquidia research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Liquidia research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Liquidia's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.